Why is it so difficult to develop a hepatitis C virus preventive vaccine?

Clinical Microbiology and Infection

Volumn 20, Issue S5, 2014, Pages 103-109

  Zingaretti, C ^a   De Francesco, R ^a   Abrignani, S ^a  

^a Istituto Nazionale di Genetica Molecolare   (Italy)

Author keywords

Chronic infection; Envelope glycoproteins; Hepatitis C; Hepatitis C virus; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ENVELOPE PROTEIN; HEPATITIS C VACCINE; MIFAMURTIDE; PEGINTERFERON; PLASMID DNA; RECOMBINANT PROTEIN; RIBAVIRIN; ANTIVIRUS AGENT; HEPATITIS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROLOGY; VIRUS TRANSMISSION; ANIMAL; DISEASE MODEL; HEPACIVIRUS; HEPATITIS C, CHRONIC; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

HEPATITIS C VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIRAL HEPATITIS VACCINES;

EID: 84897489963     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12493     Document Type: Review

References (75)

1. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58: 428-438.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
3. Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
4. Pietschmann T, Kaul A, Koutsoudakis G et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 2006; 103: 7408-7413.
5. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
6. Lindenbach BD, Murray CL, Thiel H-J, Rice CM. Flaviviridae: The Viruses and Their Replication. In: Knipe DM, Howley P, eds. Fields virology, 6th edn. New York: Lippincott Williams & Wilkins, 2013; 712-746.
7. Bartenschlager R, Penin F, Lohmann V, Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011; 19: 95-103.
8. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-107.
9. + T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005; 201: 1709-1714.
10. Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol 2013; 369: 1-15.
11. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.
12. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25: 3834-3847.
13. Jacobson IM, Davis GL, El-Serag H, Negro F, Trepo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8: 924-933, e117.
14. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-S29.
15. Sene D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004; 19: 357-381.
16. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009; 76: 818-824.
17. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011; 117: 1792-1798.
18. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36: S93-S98.
19. Piazza M, Sagliocca L, Tosone G et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997; 157: 1537-1544.
20. + cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 2005; 40: 859-867.
21. Zanetti AR, Tanzi E, Romano L et al. Multicenter trial on mother-to-infant transmission of GBV-C virus. The Lombardy Study Group on Vertical/Perinatal Hepatitis Viruses Transmission. J Med Virol 1998; 54: 107-112.
22. Weiner AJ, Thaler MM, Crawford K et al. A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. J Virol 1993; 67: 4365-4368.
23. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
24. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521, 521 e511-516.
25. Russmann S, Dowlatshahi EA, Printzen G, Habicht S, Reichen J, Zimmermann H. Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC Gastroenterol 2007; 7: 5.
26. Irving WL. Acute hepatitis C virus infection: a neglected disease? Gut 2006; 55: 1075-1077.
27. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20: 754-758.
28. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406.
29. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-1512.
30. Mehta SH, Cox A, Hoover DR et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-1483.
31. Osburn WO, Fisher BE, Dowd KA et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315-324.
32. Fafi-Kremer S, Fauvelle C, Felmlee DJ et al. Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses 2012; 4: 2016-2030.
33. Pestka JM, Zeisel MB, Blaser E et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007; 104: 6025-6030.
34. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012; 205: 763-771.
35. Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol 2002; 12: 517-523.
36. + T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 1528-1536.
37. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706-714.
38. + T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002; 35: 190-198.
39. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449-458.
40. Frese M, Schwarzle V, Barth K et al. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35: 694-703.
41. Abrignani S, Reali E, Hoghton M, De Francesco R. Hepatitis C vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds., Vaccines, 6th edn. Philadelphia: ELSEVIER Saunders, 2012; 1074-1084.
42. Fauvelle C, Lepiller Q, Felmlee DJ et al. Hepatitis C virus vaccines-progress and perspectives. Microb Pathog 2013; 58: 66-72.
43. Swadling L, Klenerman P, Barnes E. Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther 2013; 13: 1109-1124.
44. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436: 961-966.
45. Erickson AL, Houghton M, Choo QL et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993; 151: 4189-4199.
46. Frey SE, Houghton M, Coates S et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28: 6367-6373.
47. Stamataki Z, Coates S, Abrignani S, Houghton M, McKeating JA. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis 2011; 204: 811-813.
48. Kong L, Giang E, Robbins JB et al. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci USA 2012; 109: 9499-9504.
49. Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis 2013; 207 (suppl 1): S7-S12.
50. Casimiro DR, Chen L, Fu TM et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77: 6305-6313.
51. Colloca S, Barnes E, Folgori A et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012; 4: 115ra112.
52. Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12: 190-197.
53. Barnes E, Folgori A, Capone S et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4: 115ra111.
54. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002; 83: 1267-1280.
55. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20: 992-1000.
56. Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012; 36: 663-683.
57. Lambotin M, Raghuraman S, Stoll-Keller F, Baumert TF, Barth H. A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol 2010; 8: 350-360.
58. Cheent K, Khakoo SI. Natural killer cells and hepatitis C: action and reaction. Gut 2011; 60: 268-278.
59. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745-1754.
60. Timpe JM, Stamataki Z, Jennings A et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008; 47: 17-24.
61. Wiegand J, Buggisch P, Boecher W et al. Early monotherapy with pegylated interferon α-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43: 250-256.
62. Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294-1298.
63. Ray R, Meyer K, Banerjee A et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 2010; 202: 862-866.
64. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008; 8: 379-386.
65. Leroux-Roels G, Depla E, Hulstaert F et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004; 22: 3080-3086.
66. Nevens F, Roskams T, Van Vlierberghe H et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003; 38: 1289-1296.
67. Firbas C, Boehm T, Buerger V et al. Immunogenicity and safety of different injection routes and schedules of IC41, a hepatitis C virus (HCV) peptide vaccine. Vaccine 2010; 28: 2397-2407.
68. Firbas C, Jilma B, Tauber E et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006; 24: 4343-4353.
69. Klade CS, Wedemeyer H, Berg T et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008; 134: 1385-1395.
70. Wedemeyer H, Schuller E, Schlaphoff V et al. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 2009; 27: 5142-5151.
71. Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009; 11: 456-462.
72. Jacobson IM, McHutchinson JG, Boyer TD et al. GI-5005 therapeutic vaccine plus PEG-IFN/RIBAVIRIN in genotype 1 chronic HCV patients. J Hepatol 2010; 52: A2006.
73. McHutchinson JG, Jacobson IM, Boyer TD et al. GI-5005 therapeutic vaccine plus pegIFN/ribavirin improves end of treatment response at 48 weeks versus pegIFN/ribavirin in naive genotype 1 chronic HCV patients. Hepatology 2009; 50 (suppl 1): 229A.
74. Bacardi D, Amador-Canizares Y, Cosme K et al. Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus. Hum Exp Toxicol 2009; 28: 479-491.
75. Alvarez-Lajonchere L, Shoukry NH, Gra B et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2009; 16: 156-167.